ANI制药 ANIP 深 沪
已收盘 12-19 16:00:00 美东时间
82.79
-0.040
-0.05%
华盛通- 最 高85.2375
- 今 开82.87
- 成交量 45.26万股
- 最 低 79.98
- 昨 收 82.83
- 总市值 14.28亿
- 52周最高 99.50
- 市盈率 静 --
- 换手率 2.62%
- 52周最低 52.735
- 委 比 76.62%
- 总股本 1724.68万
- 历史最高 108.72
- 量 比 1.69
- 振 幅 6.35%
- 历史最低 1.10
- 每 手 1
- 风险率 14.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ANI Pharmaceuticals Announces Presentation of New Preclinical Data
In a preclinical study presented at the 2025 EULAR Congress, Purified Cortrophin Gel showed efficacy in reducing joint swelling and inflammatory cytokine response in a murine collagen-induced arthritis model, without causing additional bone turnover. The study highlights its potential for treating inflammatory arthritis conditions.
06-12 11:00
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
ANI Pharmaceuticals' CEO, Nikhil Lalwani, will present at the 2025 Jefferies Global Healthcare Conference on June 4, 2025, at 2:35pm ET. The live and archived webcast will be available on the Company’s website under the Investors section.
05-27 20:30
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares
ANI Pharmaceuticals announced a Phase 4 clinical trial comparing two dose levels of Purified Cortrophin Gel for treating acute gout flares, evaluating safety and efficacy.
05-22 10:50
ANI Pharmaceuticals Reports FDA Approval And Commercialization Of Ketoconazole Shampoo, 2%
NI's Ketoconazole Shampoo, 2% is the generic version of the reference listed drug (RLD) Nizoral. U.S. annual sales for Ketoconazole Shampoo, 2% total approximately $69.2 million, based on
2024-09-26 18:52
In-Depth Examination Of 4 Analyst Recommendations For ANI Pharmaceuticals
ANI Pharmaceuticals (NASDAQ:ANIP) has been analyzed by 4 analysts in the last t...
2024-09-17 20:01
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
2024-09-12 00:13
Truist Securities Downgrades ANI Pharmaceuticals to Hold, Lowers Price Target to $60
Truist Securities analyst Gregory Fraser downgrades ANI Pharmaceuticals (NASDAQ:ANIP) from Buy to Hold and lowers the price target from $80 to $60.
2024-09-11 18:47
